Welchol (colesevelam HCl) Receives FDA Approval to Lower LDL Cholesterol in Pediatric Patients with Heterozygous Familial Hypercholesterolemia

Welchol (colesevelam HCl) Receives FDA Approval to Lower LDL
Cholesterol in Pediatric Patients with Heterozygous Familial
Hypercholesterolemia
October 7, 2009
Welchol for Oral Suspension Also Approved by FDA

PARSIPPANY, N.J., Oct. 7 /PRNewswire/ -- Daiichi Sankyo, Inc. (DSI)
announced today that the U.S. Food and Drug Administration (FDA) has
approved the supplemental new drug application (sNDA) for Welchol
(colesevelam HCl) to be used as an adjunct to diet and exercise for
the reduction of elevated low-density lipoprotein cholesterol (LDL-C)
in boys and postmenarchal girls, 10 to 17 years of age, with
heterozygous familial hypercholesterolemia

--
twitter.com/esgdm